Personalizing health care: Feasibility and future implications

Brian Godman, Alexander E. Finlayson, Parneet K. Cheema, Eva Zebedin-Brandl, Inaki Gutiérrez-Ibarluzea, Jan Jones, Rickard E. Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Bucsics, Stephen Campbell, Eduardo Diogene, Alessandra Ferrario, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Katharine Harris, Alan HaycoxHarald Herholz, Krystyna Hviding, Saira Jan, Marija Kalaba, Christina Kvalheim, Ott Laius, Sven Ake Lööv, Kamila Malinowska, Andrew Martin, Laura McCullagh, Fredrik Nilsson, Ken Paterson, Ulrich Schwabe, Gisbert Selke, Catherine Sermet, Steven Simoens, Dominik Tomek, Vera Vlahovic-Palcevski, Luka Voncina, Magdalena Wladysiuk, Menno van Woerkom, Durhane Wong-Rieger, Corrine Zara, Raghib Ali, Lars L. Gustafsson

Research output: Contribution to journalArticle

Abstract

Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

Original languageEnglish (US)
Article number179
JournalBMC Medicine
Volume11
Issue number1
DOIs
StatePublished - Aug 13 2013

Fingerprint

Precision Medicine
Delivery of Health Care
Costs and Cost Analysis
Pharmacogenetics
Patient Care
Biomarkers
Phenotype
Drug Therapy
Therapeutics
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Drug development
  • Genomics
  • Genotyping
  • Health authorities
  • Healthcare policy
  • Personalized medicine
  • Pharmacogenetics precision medicine
  • Rational use of medicines
  • Reimbursement
  • Targeted treatments

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Godman, B., Finlayson, A. E., Cheema, P. K., Zebedin-Brandl, E., Gutiérrez-Ibarluzea, I., Jones, J., ... Gustafsson, L. L. (2013). Personalizing health care: Feasibility and future implications. BMC Medicine, 11(1), [179]. https://doi.org/10.1186/1741-7015-11-179

Personalizing health care : Feasibility and future implications. / Godman, Brian; Finlayson, Alexander E.; Cheema, Parneet K.; Zebedin-Brandl, Eva; Gutiérrez-Ibarluzea, Inaki; Jones, Jan; Malmström, Rickard E.; Asola, Elina; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Diogene, Eduardo; Ferrario, Alessandra; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel; Harris, Katharine; Haycox, Alan; Herholz, Harald; Hviding, Krystyna; Jan, Saira; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Lööv, Sven Ake; Malinowska, Kamila; Martin, Andrew; McCullagh, Laura; Nilsson, Fredrik; Paterson, Ken; Schwabe, Ulrich; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tomek, Dominik; Vlahovic-Palcevski, Vera; Voncina, Luka; Wladysiuk, Magdalena; van Woerkom, Menno; Wong-Rieger, Durhane; Zara, Corrine; Ali, Raghib; Gustafsson, Lars L.

In: BMC Medicine, Vol. 11, No. 1, 179, 13.08.2013.

Research output: Contribution to journalArticle

Godman, B, Finlayson, AE, Cheema, PK, Zebedin-Brandl, E, Gutiérrez-Ibarluzea, I, Jones, J, Malmström, RE, Asola, E, Baumgärtel, C, Bennie, M, Bishop, I, Bucsics, A, Campbell, S, Diogene, E, Ferrario, A, Fürst, J, Garuoliene, K, Gomes, M, Harris, K, Haycox, A, Herholz, H, Hviding, K, Jan, S, Kalaba, M, Kvalheim, C, Laius, O, Lööv, SA, Malinowska, K, Martin, A, McCullagh, L, Nilsson, F, Paterson, K, Schwabe, U, Selke, G, Sermet, C, Simoens, S, Tomek, D, Vlahovic-Palcevski, V, Voncina, L, Wladysiuk, M, van Woerkom, M, Wong-Rieger, D, Zara, C, Ali, R & Gustafsson, LL 2013, 'Personalizing health care: Feasibility and future implications', BMC Medicine, vol. 11, no. 1, 179. https://doi.org/10.1186/1741-7015-11-179
Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J et al. Personalizing health care: Feasibility and future implications. BMC Medicine. 2013 Aug 13;11(1). 179. https://doi.org/10.1186/1741-7015-11-179
Godman, Brian ; Finlayson, Alexander E. ; Cheema, Parneet K. ; Zebedin-Brandl, Eva ; Gutiérrez-Ibarluzea, Inaki ; Jones, Jan ; Malmström, Rickard E. ; Asola, Elina ; Baumgärtel, Christoph ; Bennie, Marion ; Bishop, Iain ; Bucsics, Anna ; Campbell, Stephen ; Diogene, Eduardo ; Ferrario, Alessandra ; Fürst, Jurij ; Garuoliene, Kristina ; Gomes, Miguel ; Harris, Katharine ; Haycox, Alan ; Herholz, Harald ; Hviding, Krystyna ; Jan, Saira ; Kalaba, Marija ; Kvalheim, Christina ; Laius, Ott ; Lööv, Sven Ake ; Malinowska, Kamila ; Martin, Andrew ; McCullagh, Laura ; Nilsson, Fredrik ; Paterson, Ken ; Schwabe, Ulrich ; Selke, Gisbert ; Sermet, Catherine ; Simoens, Steven ; Tomek, Dominik ; Vlahovic-Palcevski, Vera ; Voncina, Luka ; Wladysiuk, Magdalena ; van Woerkom, Menno ; Wong-Rieger, Durhane ; Zara, Corrine ; Ali, Raghib ; Gustafsson, Lars L. / Personalizing health care : Feasibility and future implications. In: BMC Medicine. 2013 ; Vol. 11, No. 1.
@article{efb09cef70c346d0a92cf60bbe85d897,
title = "Personalizing health care: Feasibility and future implications",
abstract = "Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.",
keywords = "Biomarkers, Drug development, Genomics, Genotyping, Health authorities, Healthcare policy, Personalized medicine, Pharmacogenetics precision medicine, Rational use of medicines, Reimbursement, Targeted treatments",
author = "Brian Godman and Finlayson, {Alexander E.} and Cheema, {Parneet K.} and Eva Zebedin-Brandl and Inaki Guti{\'e}rrez-Ibarluzea and Jan Jones and Malmstr{\"o}m, {Rickard E.} and Elina Asola and Christoph Baumg{\"a}rtel and Marion Bennie and Iain Bishop and Anna Bucsics and Stephen Campbell and Eduardo Diogene and Alessandra Ferrario and Jurij F{\"u}rst and Kristina Garuoliene and Miguel Gomes and Katharine Harris and Alan Haycox and Harald Herholz and Krystyna Hviding and Saira Jan and Marija Kalaba and Christina Kvalheim and Ott Laius and L{\"o}{\"o}v, {Sven Ake} and Kamila Malinowska and Andrew Martin and Laura McCullagh and Fredrik Nilsson and Ken Paterson and Ulrich Schwabe and Gisbert Selke and Catherine Sermet and Steven Simoens and Dominik Tomek and Vera Vlahovic-Palcevski and Luka Voncina and Magdalena Wladysiuk and {van Woerkom}, Menno and Durhane Wong-Rieger and Corrine Zara and Raghib Ali and Gustafsson, {Lars L.}",
year = "2013",
month = "8",
day = "13",
doi = "10.1186/1741-7015-11-179",
language = "English (US)",
volume = "11",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Personalizing health care

T2 - Feasibility and future implications

AU - Godman, Brian

AU - Finlayson, Alexander E.

AU - Cheema, Parneet K.

AU - Zebedin-Brandl, Eva

AU - Gutiérrez-Ibarluzea, Inaki

AU - Jones, Jan

AU - Malmström, Rickard E.

AU - Asola, Elina

AU - Baumgärtel, Christoph

AU - Bennie, Marion

AU - Bishop, Iain

AU - Bucsics, Anna

AU - Campbell, Stephen

AU - Diogene, Eduardo

AU - Ferrario, Alessandra

AU - Fürst, Jurij

AU - Garuoliene, Kristina

AU - Gomes, Miguel

AU - Harris, Katharine

AU - Haycox, Alan

AU - Herholz, Harald

AU - Hviding, Krystyna

AU - Jan, Saira

AU - Kalaba, Marija

AU - Kvalheim, Christina

AU - Laius, Ott

AU - Lööv, Sven Ake

AU - Malinowska, Kamila

AU - Martin, Andrew

AU - McCullagh, Laura

AU - Nilsson, Fredrik

AU - Paterson, Ken

AU - Schwabe, Ulrich

AU - Selke, Gisbert

AU - Sermet, Catherine

AU - Simoens, Steven

AU - Tomek, Dominik

AU - Vlahovic-Palcevski, Vera

AU - Voncina, Luka

AU - Wladysiuk, Magdalena

AU - van Woerkom, Menno

AU - Wong-Rieger, Durhane

AU - Zara, Corrine

AU - Ali, Raghib

AU - Gustafsson, Lars L.

PY - 2013/8/13

Y1 - 2013/8/13

N2 - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

AB - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

KW - Biomarkers

KW - Drug development

KW - Genomics

KW - Genotyping

KW - Health authorities

KW - Healthcare policy

KW - Personalized medicine

KW - Pharmacogenetics precision medicine

KW - Rational use of medicines

KW - Reimbursement

KW - Targeted treatments

UR - http://www.scopus.com/inward/record.url?scp=84887911877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887911877&partnerID=8YFLogxK

U2 - 10.1186/1741-7015-11-179

DO - 10.1186/1741-7015-11-179

M3 - Article

VL - 11

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 179

ER -